A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).
SourceAnti-Cancer Drugs, 23, 7, (2012), pp. 761-764
1 augustus 2012
Article / Letter to editor
Display more detailsDisplay less details
SubjectNCMLS 2: Immune Regulation ONCOL 3: Translational research; ONCOL 2: Age-related aspects of cancer; ONCOL 5: Aetiology, screening and detection
In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetinib 75 mg twice daily in a phase I trial and has shown complete response for the past 4 years. This case report raises questions regarding treatment schedule, treatment duration and management of adverse events.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.